Key result
CASZ1 T allele is linked to ~29% lower odds of apparent treatment-resistant hypertension.
Why the study?
Only a handful of genetic discovery efforts in apparent treatment-resistant hypertension (aTRH) had been described.
Are common genetic variants (SNPs) across the genome associated with apparent treatment-resistant hypertension compared with normotensive or treatment-responsive controls in European and African ancestry populations?
Case-Control (n=24,932)
Yes
Are common genetic variants (SNPs) across the genome associated with apparent treatment-resistant hypertension compared with normotensive or treatment-responsive controls in European and African ancestry populations?
Answers are grounded in this paper and cite their sources.
This multi-cohort genome-wide association study identifies and replicates the known blood pressure transcription factor locus CASZ1 as a genetic risk locus for apparent treatment-resistant hypertension.
BACKGROUND: Only a handful of genetic discovery efforts in apparent treatment-resistant hypertension (aTRH) have been described. METHODS: We conducted a case-control genome-wide association study of aTRH among persons treated for hypertension, using data from 10 cohorts of European ancestry (EA) and 5 cohorts of African ancestry (AA). Cases were treated with 3 different antihypertensive medication classes and had blood pressure (BP) above goal (systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or 4 or more medication classes regardless of BP control (nEA = 931, nAA = 228). Both a normotensive control group and a treatment-responsive control group were considered in separate analyses. Normotensive controls were untreated (nEA = 14,210, nAA = 2,480) and had systolic BP/diastolic BP < 140/90 mm Hg. Treatment-responsive controls (nEA = 5,266, nAA = 1,817) had BP at goal (<140/90 mm Hg), while treated with one antihypertensive medication class. Individual cohorts used logistic regression with adjustment for age, sex, study site, and principal components for ancestry to examine the association of single-nucleotide polymorphisms with case-control status. Inverse variance-weighted fixed-effects meta-analyses were carried out using METAL. RESULTS: The known hypertension locus, CASZ1, was a top finding among EAs (P = 1.1 × 10-8) and in the race-combined analysis (P = 1.5 × 10-9) using the normotensive control group (rs12046278, odds ratio = 0.71 (95% confidence interval: 0.6-0.8)). Single-nucleotide polymorphisms in this locus were robustly replicated in the Million Veterans Program (MVP) study in consideration of a treatment-responsive control group. There were no statistically significant findings for the discovery analyses including treatment-responsive controls. CONCLUSION: This genomic discovery effort for aTRH identified CASZ1 as an aTRH risk locus.
No takes yet. Share an insight, caveat, or question.
Irvin et al. (2019) conducted a case-control in Apparent treatment-resistant hypertension (aTRH) (n=24,932). CASZ1 locus (rs12046278 T allele) and genome-wide common genetic variants (SNPs) vs. Reference allele carriers examined against untreated normotensive controls (SBP/DBP < 140/90 mm Hg) and treatment-responsive controls (BP < 140/90 mm Hg on 1 antihypertensive medication class) was evaluated on Case-control status for apparent treatment-resistant hypertension (aTRH) vs. normotensive controls in the race-combined discovery analysis (OR 0.71, 95% CI 0.63-0.80, p=1.5 × 10-9). Carriers of the CASZ1 rs12046278 T allele had lower odds of apparent treatment-resistant hypertension compared with normotensive controls.
Synapse has enriched 10 related papers. Consider them for comparative context: